Skip to main
VALN
VALN logo

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE has demonstrated strong financial performance, with product sales increasing by 13% year-over-year, contributing to total revenue of €169.6 million in 2024, which reflects a 10% increase from 2023. Despite slower-than-expected initial sales for the Ixchiq vaccine in the U.S., the company is optimistic, anticipating that Ixchiq sales will surpass €100 million in its third year of commercialization, alongside a predicted global market exceeding $500 million annually for chikungunya vaccines. Moreover, recent regulatory approvals for Ixchiq in both the U.S. and EU bolster the company's confidence in its ability to achieve key developmental milestones while maintaining a healthy cash runway.

Bears say

Valneva SE is anticipated to confront significant financial challenges, as the company aims to reduce its operating cash burn to less than €30 million in 2025, down from over €60 million in 2024, indicating a tight financial environment. Furthermore, the company's revenue estimates for 2025 have been revised downward to €185 million from €222.5 million, reflecting declining sales projections for its vaccine candidate IXCHIQ. The adjusted earnings per share (EPS) forecast for 2025 has also been lowered to (€0.65) from (€0.53), underscoring the overall negative outlook concerning its financial performance.

Valneva SE (VALN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Sep 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.